Pelareorep Shows Immune Activation in KRAS-Mutant Tumors; Oncolytics to Present ASCO Data
ONCY has more than doubled off its 52-week low of $0.326 on light trading volume (0.3× avg).
Summary
Oncolytics Biotech will present translational data from its GOBLET and AWARE-1 trials at the ASCO 2026 Annual Meeting. The data demonstrates pelareorep's mechanism of action, showing it induces antiviral and anti-tumor immune responses, expanding tumor-reactive immune cells and correlating with tumor volume reductions in pancreatic cancer. Crucially, it highlights the expansion of mutant KRAS-specific T-cell clones, which is significant for difficult-to-treat KRAS-driven diseases. This scientific validation reinforces the drug's potential and supports the company's development plans, especially as it navigates a "going concern" warning and active capital raises. The ASCO presentation is scheduled for May 29-June 2, 2026.
At the time of this announcement, ONCY was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.3M. The 52-week trading range was $0.33 to $1.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.